For 2019 ASCPT QSP Preconference



CENTER FOR DRUG EVALUATION & RESEARCH OFFICE OF CLINICAL PHARMACOLOGY

Developing and Validating an In Silico Model for Proarrhythmia Risk Assessment Under the CiPA Initiative


Zhihua Li, PhD Division of Applied Regulatory Science Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research



Disclaimer

This presentation is not an official US Food and Drug Administration guidance or policy statement. No official support or endorsement by the US FDA is intended or should be inferred.

The Regulatory Issue: Torsade de Pointes




Current Regulatory Guidelines


- S7B: Non-clinical cardiac safety pharmacology
 - hERG potassium channel block
 - Non-clinical action potential or QT study
- E14: Human Clinical 'Thorough QT' study
 - Threshold of concern is ~2% increase in QT (very small!)
 - Most intensive and expensive clinical pharmacology study in drug development


- Primary goal is to inform whether ECG monitoring in patients is required in clinical phase 3 trials
- <u>Not</u> to inform whether a drug causes torsade de pointes

As some QT prolonging drugs do not cause torsade de pointes (More mechansitic marker assessing multichannel pharmacology needed!) FD)

Comprehensive *in vitro* **Proarrhythmia Assay** (CiPA)









Selecting and Improving the Base Model for CiPA






- Modeling dynamic drug-hERG interactions rather than using simple IC50s
 - Li Z et al. Circulation: Arrhythmia & Electrophysiology. 2017;10:e004628
- Optimizing model parameters so that the model can better recapitulate experimental data

Dutta et al. Frontiers in Physiology. 2017;8:616



Key Mechanism of TdP: Imbalance of Inward and Outward Currents



Increased ratio between inward and outward currents

Major currents modulating repolarization


Inward	Outward
ICaL (L type calcium)	IKr (potassium)
INaL (late sodium)	IKs (potassium)
	IK1 (potassium)
	Ito (potassium)

The net current between inward and outward currents reflect their balance.

Inet = ICaL+INaL+IKr+IKs+IK1+Ito

qNet: Amount of electronic charge carried by Inet

Performance of qNet on 12 CiPA Training Compounds



Simulation with 2000 ms cycle length

 Drug separation is good along all concentrations from 1x to 25x Cmax

Uncertainty Quantification for TdP Risk Assessment





ORIGINAL RESEARCH published: 21 November 2017 doi: 10.3389/fphys.2017.00917




Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for *in Silico* Proarrhythmia Risk Assessment

OPEN ACCESS

Kelly C. Chang¹, Sara Dutta¹, Gary R. Mirams², Kylie A. Beattie¹, Jiansong Sheng¹, Phu N. Tran¹, Min Wu¹, Wendy W. Wu¹, Thomas Colatsky³, David G. Strauss¹ and Zhihua Li^{1*}

- Developed a method to translate each drug's experimental uncertainty into 2000 metric values, describing the probability distribution of its TdP risk
- Found that uncertainty is lowest when drug concentration is 1-4x Cmax


Torsade Metric Score for Manual Training Data




Torsade Metric Score (qNet averaged 1-4 Cmax)

hERG (potassium channel) data: manual patch clamp Non-hERG (sodium and calcium channel) data: manual patch clamp

Torsade Metric Score for Hybrid Training Data









Evaluating and Freezing Model Prior to Validation

- On March 15th 2017, FDA held a Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting on the topic of "Model Informed Drug Development", where CiPA was presented as a potential new regulatory paradigm to seek external expert opinions
- A Validation Procedure document was vetted by CiPA In Silico Working Group and Ion Channel Working Group, and approved by Steering Committee prior to validation
 - The published CiPAORdv1.0 model and qNet (Torsade Metric Score) metric, as well as classification thresholds, were "frozen"
 - Defined two validation datasets: one manual and one hybrid, each 16 drugs
 - Defined two types of performance measurements: ranking TdP risk without specific classification thresholds, and classifying drugs into one of the three risk categories using specific thresholds
 - For each measurements three acceptable levels: minimally acceptable, good, and excellent.



Prediction of the 16 Validation Drugs (Hybrid Data)





Torsade Metric Score (qNet averaged 1-4 Cmax)

CiPA Progress and ICH Update

- FDA
- Over two validation datasets, the CiPA model/metric generally reaches pre-defined "excellent" ranking performance (5 times excellent and 1 time good), and generally "good" to "excellent" classification performance (5 times excellent, 3 good, and 2 minimally acceptable).
- In May 2018, CiPA validation results were reported to ICH
- In Nov 2018, ICH officially formed an Implementation Working Group to incorporate CiPA-like approaches into the current S7B/E14 guidelines through Questions & Answers

(https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14S7BIWG_ConceptPaper_Final_2018_1122.pdf)



Summary

- The CiPA model adopts the most stringent validation strategy for evaluating TdP risk prediction accuracy
- Some CiPA features could be generally applied to developing/validating/implementing QSP-type models for regulatory decision making
 - Multi-disciplinary team
 - Pre-specified development and validation strategy
 - A prospective design to strictly separate training from validation
 - Step-by-step documentation of the development and freezing of the model
 - Uncertainty quantification of the model input (pharmacological effects)
 - "Reality check" of nonclinical data and model predictions using clinical data

Acknowledgements



<u>CiPA Steering Committee</u>

Ayako Takei, Bernard Fermini, Colette Strnadova, David Strauss, Derek Leishman, Gary Gintant, Jean-Pierre Valentin, Jennifer Pierson, Kaori Shinagawa, Krishna Prasad, Kyle Kolaja, Natalia Trayanova, Norman Stockbridge, Philip Sager, Tom Colatsky, Yasunari Kanda, Yuko Sekino, Zhihua Li

All CiPA Working groups

- Ion Channel working group
- In silico working group
- <u>Cardiomyocyte working group</u>
- Phase 1 ECG working group

ALL contributors to CiPA (there are a lot!)

- HESI, SPS, CSRC
- FDA, EMA, PMDA, NIHS, Health Canada
- <u>Many</u> pharmaceutical and laboratory device companies
- Academic collaborators

FDA Contributors

- Norman Stockbridge
- Christine Garnett
- John Koerner
- Issam Zineh

<u>Ion channel</u>

- Wendy Wu
- Phu Tran
- Jiansong Sheng
- Min Wu
- Aaron Randolph

<u>In silico</u>

- Zhihua Li
- Sara Dutta
- Kelly Chang
- Kylie Beattie
- Xiaomei Han
- Bradley Ridder

<u>Cardiomyocyte</u>

- Ksenia Blinova
- Derek Schocken
- Li Pang

Phase 1 ECG biomarker

- Jose Vicente
- Lars Johannesen
- Meisam Hosseini
- Robbert Zusterzeel
- Murali Matta
- Roberto Ochoa-Jimenez



BACKUP

Ranking Performance



Performance Measure	Interpretation	Manual Dataset	Hybrid Dataset
AUC of ROC1	Probability of ranking an Intermediate-or-	0.89 (0.84 - 0.95)	0.98 (0.93 - 1)
	High risk drug above a Low risk drug		
AUC of ROC2	Probability of ranking a High risk drug	1 (0.92-1)	0.94 (0.88- 0.98)
	above an Intermediate-or-Low drug		
Pairwise Ranking	Probability of correctly ranking a drug	0.95 (0.92 –	0.96 (0.92- 0.99)
	relative to CiPA reference drugs through	0.98)	
	pairwise comparison across 3 categories		
Below minimally acce	eptable Minimally acceptable Good	Excellent	

For both manual and hybrid datasets, ranking performance of Torsade Metric Score all reached or are very close to excellent level.

Classification Performance

Performance Measure	Interpretation	Manual Dataset	Hybrid Dataset
LR+ of Threshold 1	How much more likely a High-or-Intermediate drug will be	4.5 (2.3 – 5)	8e5 (7e5 – 1e6)
	predicted as High-or-Intermediate, compared to a Low Risk		
	drug?		
1/LR- of Threshold 1	How much less likely a High-or-Intermediate drug will be	8.8 (4.4- 8e5)	5.5 (3.7 - 1e6)
	predicted as Low Risk, compared to a Low Risk drug?		
LR+ of Threshold 2	How much more likely a High Risk drug will be predicted as	12 (4.5 – 1e6)	6 (3 - 12)
	High Risk, compared to a Low-or-Intermediate Risk drug?		
1/LR- of Threshold 2	How much less likely a High Risk drug will be predicted as High	9e5 (3.3 – 1e6)	3.7 (3 – 9e5)
	Risk, compared to a Low –or-Intermediate Risk drug?		
Mean Classification Error	Average error of classifying each of the 16 validation drugs into	0.19 (0.17-0.21)	0.25 (0.23-0.27)
	High, Intermediate, or Low risk category		
Below minimally acc	eptable Minimally acceptable Good	Excellent	

For classification measures, Torsade Metric Score on the manual and hybrid datasets mostly hit good to excellent performance.